Navigation Links
Kensey Nash Announces Director Resignation
Date:2/4/2009

EXTON, Pa., Feb. 4 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY), a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today announced the resignation of Mr. Jeffrey C. Smith, Partner and Portfolio Manager of Ramius LLC, from its Board of Directors.

Mr. Smith became a director of Kensey Nash in December 2007 and was a member of the Corporate Governance and Nominating Committee as well as a member of the Strategic Planning Committee. Mr. Smith advised the Company that he has resigned from the Board and Board committees given time constraints and other responsibilities that demand his attention.

"On behalf of the Board, I would like to thank Jeff for his service and contributions to Kensey Nash and wish him well with his future endeavors," stated Joe Kaufmann, President and CEO.

"Over the past 14 months, the Company has accomplished a great deal in a relatively short period of time including successfully executing on the sale of the Endovascular products segment and materially increasing cash flow and earnings," commented Jeff Smith. "At this time, I must shift my focus to other opportunities which demand my attention. I enjoyed serving on the Board of Directors and look forward to monitoring the Company's continued success."

About Kensey Nash Corporation. Kensey Nash Corporation is a leading medical technology company providing innovative solutions and technologies for a wide range of medical procedures. The Company provides an extensive range of products into multiple medical markets, primarily sports medicine, spine, and endovascular markets. Many of the products are based on the Company's significant expertise in the design, development, manufacturing and processing of absorbable biomaterials, which has led to partnerships to commercialize technologies. The Company is known as a pioneer in the field of arterial puncture closure, as the inventor and developer of the Angio-Seal(TM) Vascular Closure Device, which is licensed to St. Jude Medical, Inc.


'/>"/>
SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Kensey Nash Corporation Announces Its Second Quarter 2009 Earnings Release Date and Teleconference
2. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
3. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2008 Earnings Release Date and Teleconference
4. Kensey Nash Provides 4th Quarter Fiscal 2008 and Fiscal Year 2009 Guidance
5. Kensey Nash Announces the Closing on its Sale of the Endovascular Business to Spectranetics
6. Kensey Nash to Participate in the Friedman Billings Ramsey 12th Annual Spring Investor Conference
7. Corrected Press Release: Kensey Nash to Present at the Bank of America 2008 Health Care Conference
8. Kensey Nash to Present at the Bank of America 2008 Health Care Conference
9. Kensey Nash Reports Third Quarter Record Revenue and Sales
10. Kensey Nash to Participate in the Sidoti Twelfth Annual New York Emerging Growth Institutional Investor Forum Conference
11. Kensey Nash Reports Second Quarter EPS of $0.21 and Revenue of $19.6 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... Getting enough sleep affects much more than energy – it also has mental and physical ... compromise motor reaction time, which can increase the risk of having a car accident. ... from the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... California (PRWEB) , ... April 28, 2017 , ... ... T8 Direct Replace tubes . These lamps offer an instant energy-saving solution for ... need to rewire fixtures or disconnect ballasts. These 50,000 hour rated lamps utilize ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... hERG liability could substantially improve drug safety and minimize the cost of development. ... validating ion channel inhibition using cell lines and for cardiac toxicity using induced ...
(Date:4/28/2017)... ... ... Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a new ... not. Yisrayl says with so many titles and names for the Creator, it’s hard ... a little Scripture, backed with a lot of research, the truth is undeniable. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ... their offering. ... for drug delivery technologies will rise from USD 20 Billion in ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
Breaking Medicine Technology: